The General Data Protection Regulation (GDPR), since its implementation in May 2018, has significantly reshaped data protection laws across Europe. The GDPR was implemented to address the growing concerns about privacy and data protection in the digital age. As technology advanced and data became an integral part of daily life, the European Union (EU)… Continue reading Navigating the Diverse Landscape of GDPR Interpretation in European Healthcare and Clinical Research
Category: Regulatory
EMA's Strategic Initiatives for Addressing Unmet Medical Needs
An unmet need in healthcare refers to a gap where current medical knowledge, treatments, or healthcare services do not adequately address a particular condition, disease, or health issue. These unmet needs can arise in various aspects of healthcare, such as the availability of effective treatments, access to healthcare services, or the ability to diagnose and… Continue reading EMA's Strategic Initiatives for Addressing Unmet Medical Needs
Fit-for-Purpose in RWE: Comparing Regulatory Approaches Across Global Agencies
The concept of “fitness-for-purpose” (or fit-for-purpose) is a key definition in regulatory science, as it determines whether the data, methods, or tools used in a study are suitable for their intended purpose. In particular, “fit-for-purpose” in Real-World Evidence (RWE) research refers to the suitability of the data and study design for addressing a study design… Continue reading Fit-for-Purpose in RWE: Comparing Regulatory Approaches Across Global Agencies
Leveraging Natural History of Disease Studies for Integrated Evidence Generation Plans and Regulatory Success
Natural history of disease studies are intended to track the course of a disease by identifying demographic, genetic, environmental, and other variables (e.g., treatments, concomitant medications) that correlate with the disease’s development and outcomes. Natural history of disease studies play a crucial role in integrated evidence generation plans, especially for rare diseases and conditions where… Continue reading Leveraging Natural History of Disease Studies for Integrated Evidence Generation Plans and Regulatory Success
RWD for EMA Regulatory Submissions: Differences in Use for Pre- vs. Post-Approval
Real‐world evidence (RWE) has an increasing role in both pre-, and post- approval applications to support the authorization of new medicines and indications, or to address post-marketing safety concerns. Therefore, the use of Real-World Data (RWD) in regulatory processes at the European Medicines Agency (EMA) varies depending on whether it is being used for… Continue reading RWD for EMA Regulatory Submissions: Differences in Use for Pre- vs. Post-Approval